Jove
Visualize
Contact Us

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy.

Pharmacotherapy·2026
Same author

Retrospective Analysis of Once-Daily Versus Twice-Daily Insulin Glargine Dosing in Noncritically Ill Individuals.

Diabetes spectrum : a publication of the American Diabetes Association·2024
Same author

Glucagon and Its Underutilization in Diabetes Self-Management: A Teachable Moment.

Clinical diabetes : a publication of the American Diabetes Association·2023
Same author

Significant publications in diabetes pharmacotherapy and technology in 2020.

Expert review of endocrinology & metabolism·2023
Same author

Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome.

Journal of cardiovascular pharmacology·2022
Same author

Clinical review of subcutaneous semaglutide for obesity.

Journal of clinical pharmacy and therapeutics·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 9, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K

What's new in multiple sclerosis?

Erika E Tillery1, Jennifer N Clements2, Zach Howard3

  • 1Associate Professor of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, South Carolina, etill2020@gmail.com.

The Mental Health Clinician
|June 30, 2018
PubMed
Summary
This summary is machine-generated.

New medications for relapsing-remitting multiple sclerosis (RRMS) offer comparable efficacy but varied safety profiles. Treatment selection for RRMS should consider patient preference, dosing, and potential adverse effects.

Keywords:
RRMSdisease-modifying agentsmultiple sclerosispharmacotherapyrelapsing-remittingtreatment

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.8K

Related Experiment Videos

Last Updated: Jul 9, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.8K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic neurological disease with relapsing-remitting MS (RRMS) as the most common form.
  • Recent years have seen an increase in approved treatments for RRMS.

Purpose of the Study:

  • To provide an updated overview of medications approved for RRMS treatment since January 2010.

Main Methods:

  • A literature review identified FDA-approved RRMS medications between January 2010 and April 2017.
  • Package inserts and relevant articles were analyzed for key treatment information.

Main Results:

  • Seven new medications for RRMS, including oral and injectable options, have been approved.
  • All agents demonstrate comparable efficacy, with distinct safety profiles and potential adverse effects.
  • Therapeutic choices depend on patient factors like preference, dosing, and safety.

Conclusions:

  • Multiple treatment options are now available for RRMS.
  • Optimal patient therapy requires careful consideration of adverse effects, administration route, and frequency.